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Objective: Pulmonary arteriovenous malformations occur in up to 60% of patients
after cavopulmonary anastomosis. We compared the effects of cavopulmonary
anastomosis and pulmonary artery banding on lung gene expression in an ovine
model to study the abnormal pulmonary vascular remodeling after the exclusion of
inferior vena caval blood independent of reduced pulmonary blood flow. We
previously demonstrated by contrast echocardiography that pulmonary arterio-
venous malformations develop by 8 weeks after cavopulmonary anastomosis but not
after pulmonary artery banding. Hepatocyte growth factor, a pleiotropic factor with
morphogenic, mitogenic, and angiogenic activities, signals via its specific receptor
c-Met to induce the antiapoptotic factor Bcl-2. In this study, we examined pulmo-
nary artery expression of these factors and their potential role in pulmonary artery
remodeling after cavopulmonary anastomosis and pulmonary artery banding.
Methods: Eighteen lambs aged 35 to 45 days were placed into 3 groups: cavopul-
monary anastomosis, pulmonary artery banding, and control (n  6/group). In the
cavopulmonary anastomosis group, the superior vena cava was anastomosed to the
right pulmonary artery in an end-to-end fashion. In the pulmonary artery banding
group, the left pulmonary artery was banded to reduce blood flow to 20% of control.
The control group had a simple right pulmonary artery clamp for 30 minutes. Lung
was harvested for Western blot, reverse transcriptase–polymerase chain reaction,
and immunostaining at 2 weeks (n  3/group) and 5 weeks (n  3/group) after
surgery.
Results: The expression of c-Met mRNA after cavopulmonary anastomosis was
increased by twofold compared with the control or pulmonary artery banding group.
The total lung expression of c-Met by Western blot was also up regulated at 2 weeks
(P .05). However, total lung expression of hepatocyte growth factor and Bcl-2 by
Western and reverse transcriptase–polymerase chain reaction was not different from
the control and pulmonary artery banding groups at both 2 and 5 weeks after
surgery. Immunohistochemical analysis revealed that c-Met expression was local-
ized to the intimal layer of the pulmonary artery in the cavopulmonary anastomosis,
while its expression in the control and pulmonary artery banding lungs was localized
to the medial layer. Localization of Bcl-2 on the intimal layer in lambs with
cavopulmonary anastomosis followed the same pattern as c-Met.
Conclusions: After cavopulmonary anastomosis, pulmonary artery expression of the
hepatocyte growth factor receptor c-Met and one of its downstream effectors, Bcl-2,
had increased in the intimal layer and decreased in the medial layer. Because the
hepatocyte growth factor signaling promotes increased endothelial cell survival, it
may have a role in pulmonary artery remodeling following cavopulmonary anasto-
mosis. In addition, the change of c-Met expression in the medial layer after
cavopulmonary anastomosis suggests a possible mechanism for the smooth muscle
cell alteration related to abnormal angiogenesis.
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Cavopulmonary anastomosis (CPA) is per-formed in patients with single ventriclephysiology as an interim procedure of totalcavopulmonary connection.1,2 However,pulmonary arteriovenous malformations(PAVMs) develop in a significant propor-
tion of patients undergoing CPA. Several series demon-
strated clinically significant PAVMs in up to 25% of pa-
tients after CPA3,4 and asymptomatic PAVMs in up to 60%
of patients.5 Clinical histological analysis of lung tissue
after CPA reveals the increase of pulmonary microvessel
density and dilated microvascular structures.6,7
However, the physiologic and molecular basis for this
abnormal pulmonary vascular remodeling remains unclear.
To better understand this phenomenon, we developed an
ovine model that reliably produces pulmonary arteriovenous
shunting 8 weeks after the construction of CPA. In general,
the development of PAVMs after CPA suggests an abnor-
mal form of angiogenesis. In our previous study, we re-
ported the up-regulation of the pulmonary expression of
vascular endothelial growth factor (VEGF) after not only a
CPA model but also a pulmonary artery banding (PAB)
model, which is a pulmonary blood flow–reducing model
that does not result in the development of PAVMs.8
Therefore, we focused on an alternative angiogenic fac-
tor, hepatocyte growth factor (HGF) and its specific receptor
c-Met, to determine its possible role in PAVM development
following CPA. HGF is pleiotropic protein involved in
mitogenesis, motogenesis, morphogenesis, and embryonic
organogenesis.9 The expression of c-Met in the normal lung
has not been reported so far. However, Ohmichi and col-
leagues10 reported that HGF acts a humoral mediator of
mesenchyme–epithelial interaction during fetal lung devel-
opment. Moreover, the expression of HGF in the lung has
also been verified during liver regeneration after liver inju-
ry.11 In terms of the HGF system in the vascular structure,
the expression of HGF and c-Met on the aortic endothelial
and smooth muscle cells has been verified as a local auto-
crine/paracrine HGF system, which acts as an endothelial-
specific growth factor without vascular smooth muscle cell
replication.12 Bcl2, which is an antiapoptotic factor and one
of the downstream signals of activated c-Met, has been
found to be up-regulated in a manner consistent with inhi-
bition of the endothelial cell death in response to hypoxia.13
In this study, we evaluated the expression of the HGF
system within the pulmonary artery following CPA and




Western sheep, aged 35 to 45 days (n 6), were anesthetized with
isoflurane (2%), intubated, and mechanically ventilated. After me-
dian sternotomy and pericardiotomy, the superior vena cava (SVC)
and right pulmonary artery (PA) were identified and dissected free
from their attachments. The right PA was divided near the pulmo-
nary bifurcation and the proximal end was oversewn. The SVC
was similarly divided at the cavoatrial junction and the atrial end
was oversewn. Intravenous heparin was administered (300 U/kg),
and 16F to 20F venous cannulas were placed to bypass the SVC to
the right atrium. The SVC was then anastomosed to the right PA
in an end-to-end fashion with running polypropylene sutures. The
venous cannulas were removed, and the sternum was closed. After
skin closure, the lambs were extubated and allowed to recover.
Another set of age-matched lambs underwent PAB (n  6).
After sternotomy, the left PA was dissected free from its attach-
ments. The left PA was then encircled with an umbilical tape, and
an ultrasonic flow probe (Transonic Systems, Inc, Ithaca, NY) was
placed. Once baseline flow measurements were recorded, the um-
bilical tape was tightened around the left PA with surgical clips to
reduce flow to 20% of baseline values. The band was then further
secured by 5-0 polypropylene sutures and placed in the adventitia
of the left PA.
A third group of lambs of the same age served as sham-
operated control animals (n  6). The preparation and dissection
were the same as that described for the CPA cohort. The right PA
was occluded with a vascular clamp for 30 minutes.
All of the animals in this study received humane care in
compliance with the Principles of Laboratory Animal Care, for-
mulated by the National Society of Medical Research, and the
Guide for the Care and Use of Laboratory Animals, prepared by
the Institute of Laboratory Animal Resources, National Research
Council and published by the National Academy Press, revised
1996. The protocol was approved by the Committee on Animal
Research at University California San Francisco and Stanford
University.
Tissue Harvest
Lambs were killed at 2 and 5 weeks after the operation to obtain
tissue for analysis. Animals were intubated and mechanically
ventilated. After median sternotomy, the lambs were anticoagu-
lated with sodium heparin (300 U/kg). The lambs were then killed
by the infusion of sodium pentobarbital, the lungs were removed,
and the samples were snap-frozen in liquid nitrogen. Tissue blocks
were also fixed in HistoChoice media (Amresco Inc, Solon, Ohio)
for histological analysis.
Western Blot Analysis
Specimens of the right lower lung tissue from the CPA and control
cohort and the left lower lung tissue from the PAB cohort were
obtained as described above. The specimens were homogenized,
and the proteins were extracted as previously described.14 The
proteins were then transferred to a polyvinylidene difluoride mem-
brane (Amersham Pharmacia Biotech Inc, Piscataway, NJ). The
membrane was soaked in Tris-buffered saline solution (100
mmol/L Tris-HCl, pH 7.5 and 150 mmol/L, NaCl) containing 5%
nonfat powdered milk and 0.1% Tween-20 to block nonspecific
binding. The membrane was then incubated overnight at 4°C with
the following primary antisera (all from Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif) at the specified dilutions: c-Met, 1:100;
HGF, 1:50; Bcl-2, 1:100. The blots were washed and incubated for
1 hour at room temperature with a peroxidase-conjugated second-
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ary antibody (1:30,000 dilution, Vector Laboratories, Inc, Burlin-
game, Calif). Immunoreactivity was detected with the Supersignal
chemiluminescent substrate kit (Pierce Chemical Company, Rock-
ford, Ill). Quantitative assessment of band densities was performed
using a scanning densitometry (Quntity One quantitation software,
Bio-Rad, Hercules, Calif).
Reverse Transcriptase–Polymerase Chain Reaction
Total RNA was prepared from homogenates of the right lower lobe
lung tissue from the control and CPA lambs, as well as the left
lower lobe lung tissue from the PAB studied at selected time points
after the operations. RNA was extracted with the use of the TRI
Reagent RNA isolation protocol (Molecular Research Center, Inc,
Cincinnati, Ohio). Samples were incubated with oligo (dT) primer
and reverse transcriptase (Superscript Kit; Gibco BRL, Life Tech-
nologies, Inc, Rockville, Md) at 42°C for 50 minutes. The resulting
complementary DNA underwent polymerase chain reaction (PCR)
with the use of the following primers: HGF forward primer 5'-
TGCACAATTCCTGAAAAGAC-3 and reverse primer 5'-CGGA-
CAAAAATACCAGGACG-3' (product 314 bp), c-Met forward
primer 5'-CGGTCTTCAAGTAGCCAAGG-3' and reverse primer
5'-ACCAGTTCAGAAAACGGATGG-3' (product 450 bp), and
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) forward
primer 5'-TCCTTGAGGCCATGTGGGCCAT-3', reverse primer
5'-TGATGACATCAAGAAGGTGGTGAAG-3' (product 220 bp).
PCR was initiated with 4 minutes of denaturation at 95°C followed
by 30 cycles of 30 seconds of denaturation at 95°C, 30 seconds of
annealing at 55°C, and 90 seconds of extension at 72°C, followed
by a final 7 additional minutes of extension (iCycler Thermal
Cycler, Bio-Rad). PCR products were separated in a 1.5% agarose
gel. Densitometric analysis was used to quantify the PCR signal
(Quntity One quantitation software, Bio-Rad). Density data for
each sample was normalized to its corresponding recovery control
gene (G3PDH) density prior to comparison.
Immunohistochemistry
Immunolocalization was performed as previously described.7 In
brief, lung tissue from the experimental and control animals at 2
and 5 weeks after CPA, PAB, or control surgery was fixed in
HistoChoice media. Tissue was then paraffin embedded, sectioned
at 7 m, and mounted onto glass slides. Slides were deparaffinized
by means of immersion for 3 minutes each in xylene and 100%,
95%, 70%, and 50% ethanol. Slides were washed with Tris-
buffered saline solution (TBS; 50 mmol/L, pH 7.6) and then
incubated with 0.5% hydrogen peroxide with 1 mg/mL of saponin
in TBS for 30 minutes to quench endogenous peroxidases. Sec-
tions were incubated with 5% serum from the host species for the
secondary antisera to reduce nonspecific antibody binding. Sec-
tions were also blocked using avidin and biotin blocking kit
(Vector Laboratories) for 15 minutes. Sections were incubated
for 18 hours at 4°C with primary antisera as described above.
Visualization of staining was accomplished with the Vectastain
elite ABC kit (Vector Laboratories), with diaminobenzidine as
the chromogen (DAB kit, DAKO, San Francisco, Calif).
Statistical Analysis
Data were analyzed with Statview (SAS Institute, Inc, Cary, NC).
Protein and RNA analyses were evaluated with 3 animals at both
2 and 5 weeks in the CPA, PAB, and control groups for a total of
6 animals in each cohort. Analysis of statistical differences be-
tween groups at each time point was performed by means of
nonparametric Mann-Whitney test. All values are expressed as
mean  standard error mean (SEM).
Results
HGF mRNA and Protein Expression After CPA and
PAB
We confirmed lung expression of HGF mRNA and protein
in the lung. The HGF mRNA level in the CPA group did not
reveal any differences as compared with the control and
PAB groups at 2 weeks (Figure 1, A). The HGF -chain
protein expression level in the CPA group was found to be
the same as the control and PAB groups at 2 weeks and 5
weeks (Figure 1, B).
c-Met mRNA and Protein Expression After CPA and
PAB
We demonstrated lung expression of c-Met mRNA and
protein in our model. The expression of c-Met mRNA was
increased 2.6-fold in the CPA group compared with the
control group and 3.4-fold compared with the PAB group at
2 weeks (P  .05, respectively; Figure 2, A). c-Met protein
expression was also increased 1.5-fold in the CPA group
compared with the control and PAB groups at 2 weeks and
5 weeks (Figure 2, B). We also confirmed Bcl-2 protein
expression in our lung model. However, we did not find any
significant difference in Bcl-2 protein expression among the
3 groups.
Localization of the HGF Signaling System in the Lung
HGF protein was found to be expressed in the smooth
muscle layers of both vascular and airway tissues (Figure 3).
c-Met protein was expressed in the epithelial cells and
airway smooth muscle cells in all 3 groups. In the CPA
lung, the PA expression of c-Met was predominantly ob-
served in the endothelial layer at 2 weeks and 5 weeks,
while its expression in the control and PAB lungs was
predominantly observed in the medial layer (Figure 4).
Bcl-2 expression in the CPA lung was localized to the
intimal layer, consistent with the expression of c-Met. In
contrast, Bcl-2 expression in the control and PAB lungs was
mainly restricted to the medial layer of the PA (Figure 5).
Discussion
In the present study, we confirmed the existence of HGF and
c-Met in pulmonary vessels. Under normal physiological
conditions, c-Met is barely detectable in the lung. c-Met
expression in the lung has been reported during fetal lung
development as a mesenchyme-derived morphogenic fac-
tor.10 We used a growing lamb to simulate the clinical
setting that PAVM after CPA has on younger patients who
have higher incidence of this phenomenon.15 Our results
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suggested that HGF system might support organized lung
development even after birth. We are unaware of any re-
ports pertaining to the HGF system expression in the pul-
monary vasculature in normal lungs. Therefore, we believe
that this is the first report of c-Met expression in the pul-
monary vasculature of a growing lung.
We confirmed a similar pattern of HGF localization in
the mesenchyme among the 3 groups by immunohistochem-
ical stain. Liu and colleagues16 reported increased expres-
sion of c-Met and decreased expression of HGF in the
Figure 1. Expression of HGF mRNA and protein in the lung. A,
Reverse transcriptase–polymerase chain reaction analysis of
HGF mRNA isolated from the whole lung tissue 2 weeks after
surgery. The upper image shows representative signal of 2 ani-
mals in each group. The lower image shows the result of quan-
titative analysis (n  3). B, Western blot analysis of HGF 
subunit. The upper image is a representative blot image of each
group. The upper image is after 2 weeks and the lower image is
after 5 weeks. The lower image is the result of quantitative
analysis (n  3). No statistically significant differences were
observed.
Figure 2. The expression of c-Met protein and mRNA in the lung.
A, Reverse transcriptase–polymerase chain reaction analysis of
c-Met mRNA, which has been isolated from the whole lung tissue
2 weeks after surgery. The upper image shows representative
signal of 3 animals in each group. The lower lane is the result of
quantitative analysis from the 3 animals per group. #P < .05
versus control and PAB. B, Western blot analysis of c-Met. The
left 3 lanes are control lambs. The middle 3 lanes are CPA lambs.
The right 3 lanes are PAB lambs. The upper image is after 2
weeks and the lower image is after 5 weeks. #P < .05 versus
control and PAB at 2 weeks. *P < .05 versus control and PAB at
5 weeks.
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kidney after acute renal failure. They also indicated that
circulating HGF up-regulates c-Met expression in the kid-
ney after injury. Himeno and colleagues17 reported that
HGF plasma concentration in the SVC is higher than in the
hepatic vein. In reference to these facts, although we did not
measure the plasma HGF level in this setting, we speculated
that circulating HGF induces c-Met up-regulation in an
endocrine manner. On the other hand, To and colleagues18
demonstrated that interleukin-6 up-regulated the expression
of c-Met in lung adenocarcinoma cells. These facts suggest
that the induction of c-Met expression affects not only
HGF/c-Met autocrine and paracrine mechanisms but also
affects cytokine expression. We reported the up-regulation
of oxidative stress genes in the CPA lung,8 which is con-
sistent with the possibility that a stress-promoting factor
could be present and active in the up-regulation of c-Met
expression in the lung following CPA.
We documented that the expression of c-Met mRNA and
protein level were up-regulated after CPA. In the CPA lung,
moreover, we observed a consistent shift in the expression
Figure 3. Immunohistochemical stain of HGF. The left image is control. The middle image is CPA. The right image
is PAB. Original magnification is 200. Area enlarged in inset (400) is indicated by the black rectangle. The black
bar indicates 100 m.
Figure 4. Immunohistochemical stain of c-Met. A, B, and C, after 2 weeks and D, E, and F, after 5 weeks. Both A
and D are control. Both B and E are CPA. Both C and F are PAB. The original magnification is 200. The area
enlarged in inset (400) is indicated by the black rectangle. The black bar indicates 100 m.
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of c-Met and Bcl-2 from the medial layer to the intimal
layer, while in the control and PAB lungs c-Met was ex-
pressed on the medial layer predominantly. Furthermore,
HGF has been reported to exert an endothelial-specific
effect to increase Bcl-2 expression and attenuate hypoxia-
induced endothelial cell death.13 Bcl-2 expression in the
pulmonary endothelial cell in our model may therefore
indicate activation of the c-Met signal transduction path-
way, thus promoting pulmonary endothelial cell survival
and supporting the development PAVM. Based on these
findings, our results are consistent with the fact that c-Met
up-regulation in the endothelial cell promotes angiogenesis
in vitro.19 However, we were not able to clearly confirm
significant differences in the protein expression of Bcl-2
among the 3 groups, as c-Met expression was increased.
Because Bcl-2 is not a specific downstream signal for HGF
system, its expression is likely to be affected by other
signaling molecules. Haddad and colleagues20 demonstrated
that Bcl-2 in the lung was decreased immediately after birth
and restored at a later developmental phase. In our study, we
speculate that Bcl-2 expression in this model might have
been affected by the developmental stages of this develop-
ing lamb. Furthermore, we believe that the primary impor-
tance of these signaling systems in the lung may not be the
quantitative difference in expression but rather its differen-
tial localization, which may be a more significant indicator
of physiologic differences among the three groups.
We showed the existence of HGF on the medial layer
among the 3 groups. Hayashi and colleagues21 reported that
local HGF system works in a paracrine-autocrine manner
between the endothelial cell and smooth muscle cell. HGF
is also known to have motogenic and mitogenic activity on
smooth muscle cells as well as endothelial cell.22 Bcl-2
expression in the smooth muscle cells in our control and
PAB models might indicate the effect of HGF to act as a
smooth muscle cell survival factor in an autocrine manner.
One of the distinguishing features of HGF is that it stimu-
lates the migration of vascular smooth muscle cells without
their replication, whereas VEGF dose not stimulate either
the migration or proliferation of vascular smooth muscle
cell.23 In terms of the mechanism of the development of
PAVM, our previous study documented that VEGF was
actually up-regulated in of both the CPA and PAB models.8
In the present study, we propose that changes in the HGF
signaling system in the PA, which are restricted to the
setting of CPA, might be a more important differential
factor in the development of PAVM than VEGF signaling
system. The differential expression of c-Met among the
CPA, PAB, and control groups suggests that the paracrine-
autocrine regulatory system of local HGF might be dis-
Figure 5. Immunohistochemical stain of Bcl-2. A, B, and C, after 2 weeks and D, E, and F, after 5 weeks. Both A
and D are control. Both B and E are CPA. Both C and F are PAB. The original magnification is 200. The area
enlarged in inset (400) is indicated by the black rectangle. The black bar indicates 100 m.
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rupted in response to, for example, oxidative stress or a lack
of some substance derived from hepatic venous effluent.
Interestingly, Ikai and colleagues24 reported disappearance
of hypoxic pulmonary vasoconstriction after CPA, indicat-
ing abnormal property of the peripheral PA, especially in
the smooth muscle cell, in response to alveolar hypoxia.
Moreover, the abnormal smooth muscle cell with decreased
expression of c-Met after CPA might be involved in altered
angiogenesis, resulting in the development of PAVM by
way of the HGF signaling system.
On the other hand, exclusion of inferior venocaval drain-
age from the pulmonary circulation could potentially inter-
rupt the delivery of a mediator of normal vascular develop-
ment that is derived from the liver or portal vein system.
This theory is supported by reports of the resolution of
PAVMs after the inclusion of inferior venous blood.25,26 In
hepatopulmonary syndrome, the improvement of PAVM
after liver transplantation has also been reported similarly.27
Interestingly, HGF was originally discovered as a hepato-
cyte regeneration factor9 and the HGF local expression in
the lung is up-regulated after partial hepatectomy.11 These
observations suggest that the liver and lung participate in
some endocrine cooperating system in response to the HGF
and c-Met expression. As mentioned above, HGF is also
related to lung development.10 Bernstein and colleagues15
reported that the prevalence of PAVMs was significantly
higher in infants less than 6 months old. These facts suggest
that lung development organized by the HGF signaling
system may affect the development of PAVM. Further work
is warranted to fully understand the mechanisms involved in
formation of PAVMs after CPA.
There are limitations to our study. We studied the ex-
pression of HGF system only in the early postoperative
phase. Our previous studies reported the development of
PAVMs in the lung after CPA, which occurs within 8 weeks
in all animal of our animal model. Some of the animals in
our study, however, were positive for PAVM by contrast
echocardiography within 5 weeks after CPA. Therefore, we
chose the time points of 2 and 5 weeks after surgery to
identify molecular changes that precede the development of
PAVMs. In support of our approach, we showed consistent
change of c-Met expression at 2 and 5 weeks Further study
is needed to also fully evaluate the expression of the HGF
system after the development of PAVMs.
In the present histological study, we evaluated the
slightly larger-size PA compared with the PA that has been
previously speculated to relate to PAVM development.
However, the anatomical localization of PAVMs has not
been described. From both of our previous and present
study, we were not able to define a clear explanation on the
pathological change in the development of PAVM in our
lamb model. Although the change in the expression of
c-Met in the large-size PA might not be direct evidence of
the development of PAVM, any small vessels relating to
PAVM should branch off the large PA. Further study is
needed to characterize structural histopathology of PAVMs
after CPA and the role of HGF signal transduction system in
the development of these PAVMs.
We evaluated HGF signaling system in the lung of CPA
lamb model in which development of PAVM was consis-
tently reproducible. After CPA, the expression of c-Met, a
specific receptor of HGF in the lung, increased. c-Met
localization changed in different time points from the me-
dial to intimal layer in the PA. Neither the control nor PAB
group, however, exhibited any changes in the expression of
c-Met. Bcl-2, an antiapoptotic factor, and one of c-Met’s
downstream signals showed similar localization as c-Met.
These results suggest that endothelial cell survival promoted
by HGF signaling system is a part of the mechanism respon-
sible for the development of PAVM, and in turn, the change of
c-Met expression in the medial layer after CPA suggests a
possible mechanism for the smooth muscle cell alteration
related to abnormal angiogenesis or PAVMs development.
We thank Mario Trujillo for his technical assistance.
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Discussion
Dr Steven F. Bolling (Ann Arbor, Mich). What do you con-
sider your next step? Are there either blockers of hepatocyte
growth factor or receptor blockers of the c-Met that can be used in
the system?
Dr Ikai. Maybe we can use some HGF receptor blocker for the
total animal model studied. But still they are contrary to expression
of c-Met, and the c-Met expression promotes, releases some cy-
tokine interleukin-6 or tumor growth factor-beta tumor necrosis
factor out of something. So still it’s very difficult to understand
what kind of mechanism is involved.
Dr Hikaru Matsuda (Osaka, Japan). This is a very nice study
and an interesting issue in this field of congenital heart disease. I
guess this is a very big step to go into more and to focus on what
is really the hepatic factor causing or preventing the AV malfor-
mation in the lung.
You show some included expression of HGF or c-Met receptor
in the lung, in the cavopulmonary shunt lung. And also your
previous data showed by contrast echocardiography that this
model has developed arteriovenous (AV) malformation. My ques-
tion is whether or not you have direct evidence of this change in
expression in the place where you are histologically indicating the
AV malformation in that specimen?
Dr Ikai. Actually, we didn’t figure out a specific place of the
PAVM expression in the lung. But in all of the animals after the
8th week of surgery, we have confirmed the PAVM development
by contrast echocardiography. So these lambs should have the
PAVM with some pathological changes in the lung. And mean-
while through the development of PAVM, this lung should have
some change related to that, including the hepatic vein. But we
don’t have any pathological evidence of the PAVM in this model.
Dr Matsuda. If we can get the specimen from the patient who
developed AV malformation, in that specimen we could examine
what kind of growth factor and other things have developed.
I think that the HGF and Bcl-2 can be modulated or increased
or depressed in various situations, including ischemia and other
insult, as you have included in your model. We have been studying
with another way to test whether the HGF can promote angiogen-
esis in the setting of very hypoplastic pulmonary circulation, such
as pulmonary atresia or the congenital situation.
And so far we have shown an increase in capillary density, or
number of the capillaries in the endothelial cells, but so far such
angiogenesis seems to be in a normal pattern, not abnormal an-
giogenesis suggesting the AV malformation. But we are not sure
that angiogenesis caused by HGF is not related to the malforma-
tion or just developing normal endothelial or capillary develop-
ment. Can you comment on that, the HGF effect on such a
situation?
Dr Ikai. Probably our experiment studied different parts. You
give the human recombinant HGF for the mouse or rat. I know that
result. But our model is using the very young growing lamb and
this HGF and c-Met expression spontaneously occurs in the lung.
Probably this expression relates to lung development and is still
apparent after these lung microvasculatures are developing. Maybe
this one relates to the PAVM development. So it’s a big difference
using the human recombinant for the angiogenesis spontaneously
relating the expression of c-Met and HGF in the lung.
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